Mepolizumab decreases tissue eosinophils while increasing type‐2 cytokines in eosinophilic chronic rhinosinusitis

Abstract

Mepolizumab reduced eosinophils in sinonasal tissue, demonstrating that antagonism of IL-5 suppresses eosinophil trafficking. With reduced tissue eosinophils, a local type-2 inflammatory feedback loop may occur. The study exposes mechanistic factors which may explain incomplete treatment response.